ASND Ascendis Pharma A/S

NASDAQ
$225.60

Ascendis Pharma A/S (ASND) Insider Activity

What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.

30D 90D 6M 1Y
Insider signal In line Selling ran in line with ASND's own trailing one-year pace, with 0% of sale value under a prearranged plan.
Cluster activity 0 buyers in the last 30 days 1 buyer in the last 90 days 1 seller in the last 90 days
Insiders buying
2
9 transactions
Insiders selling
2
2 transactions
Purchases
$777.1K
3,250 shares
Sales
$5.5M
22,460 shares
Net activity
-$4.7M
purchases less sales

How much of that selling was preplanned? 0% planned / 100% discretionary

10b5-1 plan sales $0 0 transactions · 0 shares
Discretionary sales $5.5M 2 transactions · 22,460 shares

Largest single sale: $4.6M.

Where they traded

Buy Sell Dot area is proportional to transaction value.

Last open-market purchase: August 14, 2026 , by BIENAIME JEAN JACQUES .

Recent open-market activity

Date Insider Role Action Shares Price Value Held after
Bodenhoff Mads SVP & PAO Sell 3,000 $270.19 $810.6K None left
BIENAIME JEAN JACQUES 2 fills Director Buy 2,000 $246.33 $492.7K 2,900
SMITH SCOTT THOMAS EVP & Chief Financial Officer Buy 100 $219.00 $21.9K 4,367
BIENAIME JEAN JACQUES 3 fills Director Buy 500 $223.12 $111.6K 900
SMITH SCOTT THOMAS EVP & Chief Financial Officer Buy 250 $223.32 $55.8K 4,267
BIENAIME JEAN JACQUES 2 fills Director Buy 400 $237.80 $95.1K 400
JENSEN FLEMMING STEEN See Remarks Sell 19,460 $238.49 $4.6M None left

Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.